https://www.selleckchem.com/pr....oducts/ozanimod-rpc1
t-like tests in ACF, relating to the accuracy of the reference standard under such conditions. Our results suggest that cheaper diagnostics do not necessarily translate to less costly ACF, as any savings from the test cost can be strongly outweighed by factors including false-positive TB treatment, reduced sensitivity, and foregone savings in second-line treatment. In resource-limited settings, it is therefore important to take all of these factors into account when designing cost-effective strategies for ACF. Our results sugge